StocksMedium•28 September 2026•
1 min read
AstraZeneca Invests $2 Billion in Summit Therapeutics for Oncology Collaboration
Key Facts
1Summit Therapeutics announced a $2 billion strategic equity investment from AstraZeneca.
2The agreement includes a clinical collaboration focused on ivonescimab and sonesitatug vedotin.
Summit Therapeutics announced a $2 billion strategic equity investment from AstraZeneca. According to Business Wire, the agreement includes a clinical collaboration focused on the development and evaluation of oncology treatments, specifically ivonescimab and sonesitatug vedotin.
SMMT closed at $15.61 on September 25, 2026, while AZN closed at $166.93 on September 28, 2026. This partnership aims to advance cancer treatment innovation through combined financial resources and clinical expertise.